XIA Shiyan, SHEN Zhuanghong, ZHANG Yingran, ZHANG Peng. Comparative study of venlafaxine sustained-release capsules and citalopram tablet in the treatment of post-stroke depression[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 173-175. doi: 10.3969/j.issn.1006-0111.2015.02.022
Citation:
|
XIA Shiyan, SHEN Zhuanghong, ZHANG Yingran, ZHANG Peng. Comparative study of venlafaxine sustained-release capsules and citalopram tablet in the treatment of post-stroke depression[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 173-175. doi: 10.3969/j.issn.1006-0111.2015.02.022
|
Comparative study of venlafaxine sustained-release capsules and citalopram tablet in the treatment of post-stroke depression
- 1.
Xiaoshan Mental Health Centre, Xiaoshan Hospital, Hangzhou 311200, China
- 2.
Xiaoshan Hospital of Chinese Traditional Medicine, Hangzhou 311200, China
- Received Date: 2013-11-14
- Rev Recd Date:
2014-03-31
-
Abstract
Objective To compare the therapeutic effectiveness and safeness of venlafaxine sustained-release capsules and citalopram tablets in the treatment of post-stroke depression. Methods 60 patients were randomly divided into venlafaxine group (n=30)and citalomram group(n=30) for 8 weeks treatment. Hamilton rating scale for depression(HAMD) and treatment emergent system scale (TESS) were used to evaluate the efficacy and side effects, respectively. Results After 4-8 weeks of treatment,both scores of HAMD of the two groups decreased significantly(P<0.05),but there was no difference between the two groups(P>0.05). The total scores of HAMD in venlafaxine group were notably lower than citalopram group after 2 weeks(P<0.05). There was no significant difference in side effects between the two groups(P>0.05). Conclusion There was no significant difference in gross curative effect and side effects between two groups; venlafaxine worked faster compared to citalopram.
-
References
[1]
|
芮 雪,范晓华,潘卫萍.脑卒中后抑郁发生率及其相关因素的调查分析[J].医学信息,2012,23(6):1939-1940. |
[2]
|
Johnson JL Minaik PA Nystrom KV,et al.Poststroke depression incidence and risk factors: an intergrave literature review[J].J Neurosci Nurs,2006,38(4 Suppl):316-327. |
[3]
|
Jia H,Damush TM,Qin H,et al.The impact of poststroke depression on healthcare use by veterans with acute stroke[J].Stroke,2006,37:2796-2801. |
[4]
|
Begre S,Traber M,Gerber M,et al.Change in pain severity with open label yenlafaxine use in patients with a depressive symptomatology: an observational study in primary care[J].Eur Psychiatr,2008,23(3):178-186. |
[5]
|
金卫东,冯 斌.文拉法辛治疗抑郁症的循证医学证据[J].四川精神卫生,2005,18(1):64. |
[6]
|
中华神经科学会,中华神经外科学会.各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379. |
[7]
|
世界卫生组织. ICD-10精神与行为障碍分类[M].北京:人民卫生出版社,1993:54. |
[8]
|
周国平,李 丹.脑卒中后抑郁的相关因素调查[J].中国误诊学杂志,2009,9(31):7807. |
[9]
|
沈渔邨. 精神病学[M].5版.北京:人民卫生出版社,2009:857. |
[10]
|
彭代辉,黄 佳.文拉法辛缓释片与文拉法辛缓释胶囊治疗抑郁症的随机、双盲对照研究[J].中国新药与临床杂志,2013,32(4):322. |
-
-
Proportional views
-